HD-OPM Archive
Topics › Insulin resistance & diabetes

Metabolic syndrome, insulin resistance and visceral fat drive plaque growth beyond LDL

Gokhan Can · Sep 28, 2025 · ♥ 9 reactions · 0 comments · original Facebook post
Insulin resistance & diabetesPlaque, CAC & CT angiographyWeight, visceral & liver fat
AI summary & key facts

An annotated evidence summary (reshared from Ken Gursky, with a long analysis) argues that residual plaque growth despite low LDL is linked to metabolic syndrome, insulin resistance and visceral fat. It cites imaging studies in which these factors predicted greater plaque progression, even on statins.

The Cardiometabolic Axis of Atherosclerosis: A Comprehensive Analysis of Insulin Resistance, Visceral Adiposity, and Metabolic Syndrome as Drivers of Coronary Plaque Progression

Beyond LDL Cholesterol: Establishing the Clinical Problem of Residual Cardiovascular Risk

##

The modern era of cardiovascular prevention has been overwhelmingly successful due to the validation of the lipid hypothesis, which establishes a causal link between high levels of low-density lipoprotein cholesterol (LDL-C) and the development of atherosclerotic cardiovascular disease (ASCVD). This understanding led to the development of powerful LDL-C-lowering therapies, primarily statins, which have become the cornerstone of cardiovascular risk reduction. Large-scale trials have unequivocally shown that lowering LDL-C dramatically reduces the incidence of major cardiovascular events.

However, despite this monumental success, a significant clinical challenge remains: a large number of patients continue to experience the progression of coronary atherosclerosis and suffer cardiovascular events even after achieving guideline-recommended, often very low, levels of LDL-C. This phenomenon, known as "residual cardiovascular risk," demonstrates that the atherosclerotic process is propelled by factors that extend beyond LDL-C concentration. A landmark pooled analysis by Bayturan et al. (2010), encompassing over 3,400 patients with coronary artery disease (CAD), brought this issue into sharp focus. The study revealed that over 20% of patients exhibited continued plaque progression even after achieving on-treatment LDL-C levels of 70 mg/dL or lower. Crucially, these "progressors" had higher baseline levels of glucose and triglycerides, pointing directly toward the role of underlying metabolic disturbances. This pivotal finding highlighted the urgent necessity to identify and target the non-lipid, metabolic drivers that perpetuate atherosclerosis.

Metabolic Syndrome as a Predictor of Plaque Growth

The metabolic syndrome (MetS) is a clinical construct designed to identify individuals with a cluster of interrelated risk factors—abdominal obesity, elevated triglycerides, low high-density lipoprotein cholesterol (HDL-C), elevated blood pressure, and elevated fasting glucose—that collectively increase the risk for ASCVD and type 2 diabetes. A substantial body of evidence now directly links MetS not just to cardiovascular events, but to the fundamental process of plaque progression itself.

A systematic review of prospective IVUS trials found that the presence of MetS was associated with a significantly greater progression of coronary plaque volume (an increase of +0.51% vs. +0.23% for those without MetS; P=.003). After adjusting for other factors, MetS was independently associated with a 25% greater likelihood of plaque progression (adjusted odds ratio [OR], 1.25). More recent evidence from the large-scale PARADIGM registry confirmed these findings, showing that MetS is an independent predictor of rapid plaque progression (an increase in plaque volume of ≥1.0% per year), with an odds ratio of 1.51. Interestingly, a crucial nuance emerged from the IVUS analysis: when individual components of MetS were analyzed, hypertriglyceridemia and obesity emerged as the primary drivers, suggesting that MetS is a valuable clinical signpost for the underlying pathophysiological processes—particularly insulin resistance—that are the true engines of the disease.
Insulin Resistance: An Independent Engine of Plaque Development and Vulnerability

While MetS groups together key risk factors, a growing consensus identifies insulin resistance (IR) as its central pathogenic core. IR is a condition where the body's cells fail to respond efficiently to insulin, leading to compensatory hyperinsulinemia and a cascade of metabolic derangements. Prospective imaging studies have established IR as a powerful and independent driver of coronary plaque growth.

A pivotal prospective study by An et al. (2012) demonstrated this connection using serial coronary angiography. The study found that individuals in the highest quartile of HOMA-IR experienced significantly greater progression of their coronary lesions (a change in Gensini score of 8.13 vs. 4.65 for those with lower HOMA-IR). Most importantly, multivariate analysis confirmed that a high HOMA-IR was a potent independent predictor for plaque progression, conferring a nearly five-fold increased risk (OR = 4.969). This profound association held true for both diabetic and non-diabetic individuals, proving that IR is a fundamental driver of atherogenesis even before the onset of overt high blood sugar.
Visceral Adiposity: A Depot-Specific Driver of High-Risk Plaque

Abdominal obesity is a cornerstone of the MetS diagnosis, but not all body fat is equally harmful. A critical distinction exists between subcutaneous fat and visceral adipose tissue (VAT), which is deposited deep within the abdominal cavity. A wealth of evidence indicates that VAT is a uniquely metabolically active and pro-inflammatory depot that specifically drives the development of high-risk, vulnerable coronary plaque.

A seminal study by Ohashi et al. (2010) used CCTA to investigate this relationship. The results were striking: after multivariate analysis, increased VAT area was significantly and independently associated with both the presence (OR: 1.68) and the extent (OR: 1.31) of non-calcified coronary plaques (NCPs). In stark contrast, other measures of adiposity like BMI showed no such association. Furthermore, increased VAT was independently associated with key features of plaque vulnerability, suggesting that visceral adiposity actively promotes a more dangerous, rupture-prone plaque phenotype. The proximity of epicardial fat to the coronary arteries allows for an additional, direct paracrine effect, bathing the vessels in inflammatory mediators and intensifying local plaque development.
The Temporal Link: Early Insulin Resistance and the Genesis of Subclinical Atherosclerosis

The strongest argument for a causal relationship comes from long-term observational studies. The Coronary Artery Risk Development in Young Adults (CARDIA) study provides definitive evidence, demonstrating that insulin resistance in young adulthood is a powerful predictor of subclinical atherosclerosis decades later. An analysis of CARDIA participants over a 25-year follow-up period found a clear temporal link. After full adjustment for other risk factors, individuals who followed a trajectory of "moderate" or "high" insulin resistance over 25 years were significantly more likely to have developed coronary artery calcification (CAC) by middle age, with odds ratios of 1.40 for the moderate-IR group and 1.84 for the high-IR group, compared to those who maintained low IR. This dose-response relationship strongly supports a causal role for sustained insulin resistance in the very initiation of the atherosclerotic process.
The Pathophysiological Nexus: Mechanisms of Metabolically-Driven Atherogenesis

The robust clinical evidence linking IR, VAT, and MetS to plaque progression is explained by a multi-pronged assault on the vasculature, orchestrated through four interconnected domains.

  1. Atherogenic Dyslipidemia: The dyslipidemia of IR is a triad of elevated triglycerides, low HDL-C, and a preponderance of small, dense LDL (sdLDL) particles. This process begins with IR in adipose tissue, leading to an excessive release of fatty acids. The liver responds by overproducing triglyceride-rich VLDL, which remodels LDL into smaller, more atherogenic particles and accelerates the clearance of protective HDL.
  2. Endothelial Dysfunction: The vascular endothelium is a critical regulator of vascular health. IR directly disrupts this balance by selectively impairing the protective, nitric oxide (NO)-producing insulin signaling pathway, while leaving a pro-atherogenic, growth-promoting pathway intact. This leads to diminished production of protective NO and enhanced production of harmful vasoconstrictors.
  3. Chronic Inflammation from Visceral Adipose Tissue: VAT is a highly active endocrine organ that, when dysfunctional, becomes a primary source of chronic, low-grade inflammation. It overproduces pro-inflammatory cytokines like TNF-α and IL-6, which act on the vasculature to promote endothelial dysfunction and accelerate every step of the atherosclerotic process.
  4. The Pro-thrombotic State: The most devastating consequences of atherosclerosis are triggered by the formation of an occlusive thrombus on a ruptured plaque. IR creates a pro-thrombotic state by impairing the body's ability to break down clots (impaired fibrinolysis) and enhancing its tendency to form them (enhanced coagulation).

Clinical Implications: From Risk Stratification to Targeted Therapy

This understanding necessitates a paradigm shift in clinical practice, moving beyond a narrow focus on LDL-C to a comprehensive evaluation of metabolic health.

Risk Assessment:

Therapeutic Strategies:

A Unified Model and Conclusion

The extensive evidence linking metabolic dysfunction to atherosclerosis does not refute the foundational lipid hypothesis; rather, it provides a deeper, more comprehensive framework. The insulin resistance paradigm subsumes and expands upon the LDL-centric model. IR is the upstream metabolic engine that manufactures the most dangerous atherogenic lipid profile, while simultaneously promoting vascular injury through parallel, lipid-independent pathways. This unified model explains the clinical problem of residual risk: a patient with well-controlled LDL-C can still experience rapid plaque progression because the other pathogenic pathways driven by their underlying IR remain highly active.

The future of effective cardiovascular prevention must be holistic and metabolically informed. It requires clinicians to look beyond the standard lipid panel and actively assess and manage the underlying metabolic health of their patients. This comprehensive approach offers the greatest promise for mitigating the vast burden of residual cardiovascular risk that continues to drive morbidity and mortality worldwide.

This is an AI summary of the papers in the original post: facebook.com/groups/710884327310801/posts/1122844689448094

Research cited

Shared from Ken Gursky · original post

It's not just about LDL, triglycerides, and HDL....

Using ChatGPT to look for the evidence that I am on the right track, which I knew I was

Plaque Drivers Summary

Annotated Summary of Key Evidence Linking Metabolic Syndrome, Insulin Resistance, and Visceral Fat to Coronary Plaque Progression

  1. Metabolic Syndrome → Coronary Plaque Progression

Bayturan et al., JAMA Internal Medicine, 2010
Design: Prospective, serial coronary imaging (angiography and IVUS)
Population: Patients with established CAD
Finding: Presence of metabolic syndrome predicted greater progression of coronary atherosclerosis despite statin therapy.
Strength: Large sample, direct imaging of plaque progression.

Paper · JAMA Internal MedicineJAMA Internal Medicine articlejamanetwork.com
  1. Insulin Resistance → Plaque Growth

An et al., Cardiovascular Diabetology, 2012
Design: 1-year prospective follow-up with IVUS
Population: Patients with stable angina
Finding: Higher insulin resistance (HOMA-IR) independently predicted progression of de novo atherosclerotic plaques.
Strength: Direct mechanistic link between IR and plaque progression, controlled for other risk factors.
Farhan et al., Cardiovascular Diabetology / PROSPECT analysis, 2021
Design: Post-hoc analysis of large plaque-characterized cohort
Finding: Insulin resistance was associated with high-risk plaque features and worse cardiovascular outcomes.

Paper · Cardiovasc Diabetol · 2012Insulin resistance predicts progression of de novo atherosclerotic plaques in patients with coronary heart disease: a one-year follow-up studyBackground The aim of our study was to explore and evaluate the relationship between insulin resistance and progression of coronary atherosclerotic plaques. With the great burden coronary heart disease is imposing on individuals, healthcare professionals have already embarked on determining its potential modifiable risk factors in the light of preventive medicine. Insulin resistance has been generally recognized as…cardiab.biomedcentral.com
  1. Visceral Fat → Non-Calcified & Progressive Coronary Plaque

Ohashi et al., JACC Imaging, 2010
Design: CT-based cross-sectional study
Population: Adults undergoing coronary CT angiography
Finding: Abdominal visceral fat volume correlated with the presence and extent of non-calcified coronary plaques.
Imai et al., 2012 (CT angiography cohort)
Design: Prospective cohort with repeat coronary CT
Finding: Visceral abdominal fat accumulation predicted progression of coronary lesions.
Additional Imaging Studies (2015–2021)
Epicardial and pericardial fat linked to greater coronary artery calcification (CAC) and non-calcified plaque burden.

Paper · JACC: Cardiovascular Imaging · 2010Association Between Visceral Adipose Tissue Area and Coronary Plaque Morphology Assessed by CT Angiographyjacc.org
  1. Long-Term Risk from Insulin Resistance

Ke et al., Journal of the American Heart Association, 2023
Design: Large young adult cohort followed for decades
Finding: Higher long-term IR predicted later development of coronary artery calcification (CAC) in middle age.
Strength: Strong temporal evidence for causality.

Paper · JAHA · 2023Long‐Term High Level of Insulin Resistance Is Associated With an Increased Prevalence of Coronary Artery Calcification: The CARDIA StudyBackground Coronary artery calcification (CAC) is a crucial indicator of subclinical atherosclerotic cardiovascular disease. The relationship between long‐term insulin resistance (IR) trajectory and CAC has been explored in few studies. Therefore, this study aimed to investigate whether the long‐term IR time series of young adults are associated with the incidence of CAC in midlife. Methods and Results In a cohort…ahajournals.org
  1. Mechanistic & Review Evidence

Di Pino & DeFronzo, Endocrine Reviews, 2019; Tune et al., 2017
Summary: Insulin resistance and metabolic syndrome promote atherogenesis via:
Dyslipidemia (↑ triglycerides, ↓ HDL, small dense LDL)
Endothelial dysfunction
Pro-inflammatory and pro-thrombotic state
Adipokine dysregulation from visceral fat

endocrine.orgInsulin Resistance and Atherosclerosis: Implications for Insulin Sensitizing AgentsIn this review the roles of insulin resistance and the IRS in the development of atherosclerotic CV disease and the impact of the insulin-sensitizing agents and of other antihyperglycemic medications on CV outcomes are discussed.endocrine.org
  1. Contemporary Imaging Consortium Evidence

Neglia et al., Circulation: Cardiovascular Imaging, 2024 (PARADIGM data)
Design: Multicenter imaging registry with serial CT angiography
Finding: Clusters of cardiometabolic abnormalities (including IR & visceral adiposity) predicted rapid plaque progression and adverse clinical outcomes.

Paper · Circ: Cardiovascular Imaging · 2024Rapid Plaque Progression Is Independently Associated With Hyperglycemia and Low HDL Cholesterol in Patients With Stable Coronary Artery Disease: A PARADIGM StudyBACKGROUND: We assessed whether combinations of cardiometabolic risk factors independently predict coronary plaque progression (PP) and major adverse cardiovascular events in patients with stable coronary artery disease. METHODS: Patients with known or suspected stable coronary artery disease (60.9±9.3 years, 55.4% male) undergoing serial coronary computed tomography angiographies (≥2 years apart), with clinical…portal.fis.tum.de

Overall Takeaway:

Metabolic syndrome, insulin resistance, and visceral adiposity are independent and synergistic drivers of coronary atherosclerosis.
They predict not only plaque presence but also progression and high-risk morphology, strengthening the argument for aggressive metabolic risk modification in prevention of CAD.

#plaque#insulin#insulinresistance#cardiovascular#metabolicsyndrome#atherosclerosis#triglycerides#visceralfat
← newer: Stem cell therapy reversed stroke damage in miceolder: Lifelong lower LDL adds about 1.2 years of life per SD, and →